About Tr1X
Tr1X is a company based in San Diego (United States) founded in 2018 by David De Vries and Maria Grazia Roncarolo.. Tr1X has raised $75 million across 3 funding rounds from investors including ARE, The Column Group and CIRM. The company has 34 employees as of December 31, 2024. Tr1X offers products and services including TRX103 and Regulatory T Cell-Based Products. Tr1X operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, Poseida Therapeutics and Juno Therapeutics, among others.
- Headquarter San Diego, United States
- Employees 34 as on 31 Dec, 2024
- Founders David De Vries, Maria Grazia Roncarolo
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Tr1x Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$75 M (USD)
in 3 rounds
-
Latest Funding Round
$8 M (USD), Grant
Apr 07, 2025
-
Investors
ARE
& 3 more
-
Employee Count
34
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Tr1X
Tr1X offers a comprehensive portfolio of products and services, including TRX103 and Regulatory T Cell-Based Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Phase 1/2a clinical trial product for treating autoimmune diseases.
Engineered cells to restore immune tolerance in inflammatory conditions.
Unlock access to complete
Funding Insights of Tr1X
Tr1X has successfully raised a total of $75M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $8 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $8.0M
-
First Round
First Round
(17 Jan 2024)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2025 | Amount | Grant - Tr1X | Valuation |
investors |
|
| Jun, 2024 | Amount | Grant - Tr1X | Valuation |
investors |
|
| Jan, 2024 | Amount | Series A - Tr1X | Valuation | TCG |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Tr1X
Tr1X has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, The Column Group and CIRM. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in US life science startups are focused on.
|
Founded Year | Domain | Location | |
|
Neva SGR is engaged in venture capital investments globally.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Tr1X
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Tr1X
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tr1x Comparisons
Competitors of Tr1X
Tr1X operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, Poseida Therapeutics and Juno Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tr1x
Frequently Asked Questions about Tr1X
When was Tr1X founded?
Tr1X was founded in 2018 and raised its 1st funding round 6 years after it was founded.
Where is Tr1X located?
Tr1X is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Tr1X?
Bill Lis is the current CEO of Tr1X.
Is Tr1X a funded company?
Tr1X is a funded company, having raised a total of $75M across 3 funding rounds to date. The company's 1st funding round was a Series A of $75M, raised on Jan 17, 2024.
How many employees does Tr1X have?
As of Dec 31, 2024, the latest employee count at Tr1X is 34.
What does Tr1X do?
Tr1X was founded in 2018 in San Diego, United States, within the biotechnology sector. A proprietary platform is utilized by the company to generate cell therapy products aimed at restoring immune tolerance. These products target autoimmune and inflammatory diseases, with operations focused on research and development in T cell therapies. Key personnel include co-founders David De Vries and Maria Grazia Roncarolo, alongside CEO Bill Lis.
Who are the top competitors of Tr1X?
Tr1X's top competitors include ADMA Biologics, Juno Therapeutics and Lyell Immunopharma.
What products or services does Tr1X offer?
Tr1X offers TRX103 and Regulatory T Cell-Based Products.
Who are Tr1X's investors?
Tr1X has 4 investors. Key investors include ARE, The Column Group, CIRM, and Neva SGR.